The results of Hu et al. (2019[32]), obtained for NSCLC Chinese patients indicate that the effect of EGFR-TKIs is also good in patients with mutations of the HER2 gene (Michelotti et al., 2022[58]; Uy et al., 2022[86]) and germline BRCA mutations (Hu et al., 2019[32]). Here, EGFR is linked to non-small cell lung carcinoma.